The Medicines and Healthcare products Regulatory Agency of Great Britain (MHRA) has approved a drug based on monoclonal antibodies Sotrovimab (Sotrovimab, trademark Xevudy). This is stated on the website of the regulator, writes UNN.
"Another treatment for COVID-19, Xevudy (Sotrovimab), was approved today by the MHRA after it was found to be safe and effective in reducing the risk of hospitalization and death in people with mild to moderate COVID-19 who are at increased risk of developing severe disease," the regulator said in a statement.
For example, a single dose of the drug reportedly reduced the risk of hospitalization and death by 79% in high-risk adults with symptomatic infections, according to clinical trial results.
According to the MHRA, it's too early to tell if the treatment is effective against the new Omicron variant.
However, according to one of the developers, GSK, it may be effective against the new variant.
Recall that the first person infected with the B.1.1.529 strain was recently found in Botswana. According to local radio station SABC, the person in question is a citizen of South Africa. The World Health Organization has named the new strain COVID-19 with the Greek letter Omicron. The organization has qualified the new variant as worrisome.
The new strain has already been detected in several European countries, the United States, Israel, Hong Kong, Japan, Canada and Australia. Many countries have begun restricting or banning travel from Southern Africa to curb the spread of the variant.